Clinical Trial Update: A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia [Phase 3]

View source ↗

Summary

A 56-week extension of a Phase 3 study assessing the efficacy and safety of vildagliptin versus placebo in drug-naive patients with type 2 diabetes and mild hyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED